Jazz Pharmaceuticals, Inc.

JAZZ XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

14B

Short interest (May 15)

7.7%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.27%

↓ 1.4%

Available Shares

↓ 23.1%

Price Chart

Company Overview

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001232524

Asset Type: CS

Market Data

Market Cap: $14,187,406,458

Employees: 2,890

Status: Active

Short Interest

Current Borrow Fee 0.27%

Range: 0.25% - 0.27%

Available Shares 1M

Range: 900K - 950K

Recent Changes

Fee Change: ↓ 8.7%

Available Change: ↓ 0.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime